摘要:
K13-propeller polymorphism is a useful molecular marker for tracking the emergence and spread of ART-resistant P. falciparum. The invention encompasses methods, compositions, and kits for detecting and genotyping Plasmodium, for example, Plasmodium falciparum. The methods, compositions, and kits can be used to detect the presence or absence of a mutated K-13 propeller nucleic acid or protein in the sample.
摘要:
The invention relates to the use of a DEAD-box RNA helicase from a yeast, a mammal, Leishmania infantum, or fragments thereof for inducing the production of cytokines by a peripheral blood mononuclear cell (PBMC) of a mammal, and to the applications thereof.
摘要:
Method for the production of high-level soluble human recombinant interferon alpha protein (rhuIFNα) in E. coli and vectors useful for such a production. Said method comprises the steps of: (1) Transforming an E. coli selected in the group consisting of E. coli protease deficient host strains, and E. coli reductase deficient host strains, with a recombinant expression vector comprising the sequence encoding the glutathione-S-transferase (GST), a junction sequence including a recognition site for a specific protease and a sequence able to encode an interferon alpha (IFN alpha) protein under the control of an inducible promoter, said vector encoding a GST-IFN alpha fusion protein (2) Expressing said interferon alpha protein in conditions comprising the induction of the expression with 0.1 mM-0.5 mM IPTG and a growth temperature of 25° and/or 37°C, depending on said E. coli strain and (3) Isolating the expressed IFN alpha protein.
摘要:
The present invention relates to new proteins of Leishmania major and to therapeutical and diagnostic applications thereof. More particularly, the present invention relates to excreted/secreted polypeptides and polynucleotides encoding same, compositions comprising the same, and methods of diagnosis, vaccination and treatment of Leishmaniasis.
摘要:
The present invention relates to a novel form of core+1 protein of Hepatitis C virus (HCV), designated shorter form core+1 protein. The shorter form core+1 protein of Hepatitis C virus is the product of translation of a coding sequence consisting of all or part of a nucleotide sequence extending from nucleotide 598 to nucleotide 920 within the core+1 ORF of HCV represented on Figure 3B. The invention also provides methods for detecting infection by Hepatitis C virus in biological samples, methods of screening compounds which interact with viral propagation in HCV infected cells or screening of compounds impaction on the expression of shorter form core+1 protein and uses of these compounds for the preparation of compositions useful for their anti-viral activities.
摘要:
The liposomes of the invention comprise at least one dual layer comprising a mixture formed by a phospholipid (I) with a flow temperature of 20-25 DEG C, and a phospholipid (II) with a flow temperature of 20-60 DEG C. The invention is characterized in that the molar ratio of phospholipid (I) to phospholipid (II) is 5:95 - 30:70. Said liposomes are for use in the production of vaccines.
摘要:
Shuttle vectors for the introduction of DNA into mycobacteria comprising at least one functional replication origin in said mycobacteria, another functional replication origin in other bacteria, an enzymatic cleavage site providing for the insertion of DNA coding for a protein susceptible of being expressed in the mycobacteria, characterized in that the vectors also carry a gene which makes the mycobacteria resistant to a compound containing a heavy metal.
摘要:
Combined use of at least two genetic markers selected from apolipoprotein E, D19S178 and apolipoprotein CII, for the diagnosis of Alzheimer's disease, especially apolipoprotein ε4, long apolipoprotein CII (30+/-3 repeat patterns (CA) and short D19S178 (less than 167+/-4 nucleotides) alleles. The invention also concerns a method for the diagnosis of Alzheimer's disease and a kit for carrying out said method.
摘要:
The liposomes of the invention comprise at least one dual layer comprising a mixture formed by a phospholipid (I) with a flow temperature of 20-25 °C, and a phospholipid (II) with a flow temperature of 20-60 °C. The invention is characterized in that the molar ratio of phospholipid (I) to phospholipid (II) is 5:95 - 30:70. Said liposomes are for use in the production of vaccines.